Today's episode is a compilation of a few short monologues. We provide an oncologist's evidence-based medicine perspective on four papers: CheckMate 274, adjuvant nivolumab in urothelial cancer; PARADIGM-HF/Entresto; the POLO trial, olaparib in pancreas cancer; and the paper "An algorithmic approach to reducing unexplained pain disparities in underserved populations".

CheckMate 274: doi.org/10.1056/NEJMoa2034442
PARADIGM-HF: doi.org/10.1056/nejmoa1409077
POLO: doi.org/10.1056/NEJMoa1903387
Knee pain: doi.org/10.1038/s41591-020-01192-7

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.11 CheckMate 274, PARADIGM-HF/Ernesto, POLO, & an AI Approach to Reducing Knee Pain

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Patient advocates, Pharma funding, and is MRD a suitable endpoint

Patient advocates funded by Pharma

FDA makes MRD the basis for AA

Another flawed quality metric. Reviewing the NEJM paper "Beta-Blockers After Myocardial Infarction and Preserved Ejection Fraction".

4.11 CheckMate 274, PARADIGM-HF/Ernesto, POLO, & an AI Approach to Reducing Knee Pain

Download our free app to listen on your phone